"Commentary on opium use and mortality in Golestan cohort study"

Archives of Iranian Medicine

Volumn 15, Issue 9, 2012, Pages 588-590

  Reece, Albert Stuart ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; DOSE RESPONSE; DRUG USE; ESOPHAGUS CANCER; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INTRAVENOUS DRUG ABUSE; IRAN; LUNG CANCER; MORTALITY; OBESITY; OBSERVATIONAL STUDY; OPIATE ADDICTION; PREDICTIVE VALUE; PREVALENCE; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; URBAN POPULATION;

EID: 84866021408     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Khademi H, Malekzadeh R Pourshams A, Jafari E, Salahi R Semnani S, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ. 2012; 344: e2502.
2. Dhalla IA. Opium, opioids, and an increased risk of death. BMJ. 2012; 344: e2617.
3. Darke S, Duflou J, Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2010; 106: 1-6.
4. Degenhardt L, Randall D, Hall W, Law M, Butler T. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend. 2009; 105: 9-15.
5. Smyth B, Hoffman V, Fan J, Hser YI. Years of potential life lost among heroin addicts 33 years after treatment. Preventive medicine. Prev. Med. 2007; 44: 369-374.
6. Rosen D, Smith ML, Reynolds CF. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry. 2008; 16: 488-497.
7. Reece AS. Differing age related trajectories of dysfunction in several organ systems in opiate dependence. Aging Clin Exp Res. 2011.
8. Reece AS, Davidson P. Deficit of circulating stemprogenitor cells in opiate addiction: a pilot study. Substance abuse treatment, prevention, and policy. Subst Abuse Treat Prev Policy. 2007; 2: 19-28.
9. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Research. 2002; 38: 351-376.
10. Wang X, Loram LC, Ramos K, de Jesus AJ, Thomas J, Cheng K, et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci USA. 2012; 109: 6325-6330.
11. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the Pharmaco-logic Basis of Therapeutics. Eleventh Edition eds. New York: McGraw Hill; 2006.
12. van Doorn R, Lopes Pinheiro MA, Kooij G, Lakeman K, van Het Hof B, van der Pol SM, et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J Neuro-inflammation. 2012; 9: 133.
13. Negishi H, Yanai H, Nakajima A, Koshiba R, Atarashi K, Matsuda A, et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol. 2012; 13: 659-666.